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for any avoided severe complication. In the univariate sensitivity analysis the ICER 
result was especially sensible to CA total cost and in a lesser extension to MICS total 
costs. The probabilistic sensitivity analysis shows the robustness of the results. The 
37.8% of the results were cost saving respect to CA. The Willingness To Pay (WTP) 
acceptability curves show that MICS compared to CA, had a higher probability to be 
accepted for the all the WTP values above US$16.000. ConClusions: MICS shows 
a better cost-effectiveness ratio than CA, with an ICER of US$8.326. The univariate 
sensitivity analysis shows the ICER result was especially sensible to CA total costs. 
The probabilistic analysis shows that in 36.8% of Monte Carlo simulations, MICS 
was cost saving respect to CA.
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objeCtives: To compare clopidogrel/aspirin with ticagrelor/aspirin in terms of 
costs and effects, from the perspective of the Mexican public health care sys-
tem. Methods: A markov model was designed to take into account all relevant 
outcomes reported in the PLATO study, allowing the evaluation of two differ-
ent cohorts of patients according to their renal function (< 60 mL/min creatinine 
clearance and ≥ 60 mL/min). The effectiveness measures analyzed were life years 
gained and events (bleeding, stroke and MI) averted. Annual cost of antiplatelet 
therapy was estimated with unit prices of the IMSS, while costs of diseases were 
taken from DRGs of the IMSS. 5 years horizon was used, so future costs were dis-
counted at 5% discount rate. Probabilistic sensitivity analysis was performed with 
1000 iterations via Monte Carlo simulations. Results: Total expected costs per 
patient were US$17,121 and US$17,697 respectively for both cohorts of clopidogrel 
while the costs for the two cohorts of ticagrelor were US$18,430 and US$18,261 
respectively. The treatment with clopidogrel resulted in less outcomes per patient 
(bleeding: 0.67 and 0.55; stroke: 0.09 and 0.083; MI: 0.51 and 0.49) than ticagrelor 
(bleeding: 0.76 and 0.59; stroke: 0.1 and 0.085; MI: 0.53 and 0.5); therefore the 
pharmacoeconomic profile of clopidogrel in comparison with ticagrelor is more 
favorable in the current study. Sensitivity analysis showed that clopidogrel has a 
higher probability of being a cost-saving option versus ticagrelor for both cohorts 
of patients. ConClusions: The economic evaluation of clopidogrel/aspirin ver-
sus ticagrelor/aspirin, taking into account relevant outcomes as well as primary 
endpoints of clinical trials, has proven that cost-effectiveness results may vary 
depending of the renal function of patients, thus giving a broader picture of the 
problem to decision makers.
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objeCtives: To compare the incremental cost-effectiveness ratio (ICER) of the 
reversible direct thrombin inhibitor dabigatran 150mg BID with those of the Xa 
factor inhibitors rivaroxaban and apixaban from the Mexican public health insti-
tution perspective. Methods: The ICER´s were calculated using a Markov model 
with a 10-year time horizon for patients over 65 and diagnosed with atrial fibril-
lation. Each treatment arm started with a cohort of 10,000 patients. The clinical 
events tracked were incorporated: ischemic stroke, systematic embolism, transient 
ischemic stroke, hemorrhagic stroke, intracranial hemorrhage, extracranial hemor-
rhage, acute myocardial infarction, minor bleed and death. Transition probabilities 
were calculated based on indirect comparisons of published phase III clinical tri-
als. Costs are adapted to the Mexican public health institution perspective. Costs 
were calculated using published literature, and national costs taken from pharma-
ceutical companies and public health institutions. Cost-effectiveness was based 
on the 1GDP per capita threshold established by the National Health Council in 
Mexico. Costs and outcomes were discounted at a 5% annual-rate. Deterministic 
and probabilistic sensitivity analyses were performed to evaluate the uncertainty 
of the variables. Results: Dabigatran was found to be dominant when compared 
with rivaroxaban and apixaban. A reduction on risk for cardiovascular complica-
tions was the key advantage of dabigatran. Dabigatran was also more effective when 
compared with warfarin (69,435 vs. 68,373 life years gained) although more costly 
(USD$192.76 vs USD$190.73 million dollars). The ICER was USD $1,910.43 per life year 
which is considered highly cost-effectiveness. The Incremental Cost-Utility Ratio per 
QALY gained was USD$1,549.00. ConClusions: The ICER and ICUR of Dabigatran 
are well below 1GDP (USD$ 10,483.26) per capita versus warfarina. Dabigatran was 
found to be dominant in comparison with all other treatments. As such, dabigatran 
can be considered a very cost-effective intervention for the Mexican population 
over 65 with atrial fibrillation.
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objeCtives: To identify the incremental cost-effectiveness ratio (ICER) for the 
treatment of inoperable patients with severe symptomatic aortic valve stenosis 
(SAS) using transcatheter aortic valve replacement (TAVR), compared to the stand-
ard of care (SoC), from the Mexican public payer perspective. Methods: A previ-
ously published decision analytical model was adapted to the Mexican setting to 
predict clinical endpoints and costs over 10 years and discounted at 5%. Mexican 
epidemiological data were applied. We performed a systematic review of published 
clinical trials to obtain the necessary clinical information to evaluate the impact 
of TAVR and SoC in the short and long term evolution of patients. Direct public 
health care costs were estimated from published literature and governmental data-
bases. Resource utilization patterns were derived from Mexican Clinical Practice 
Guidelines. The ICER was computed as incremental cost per life-year gained (LYG). 
Probabilistic and deterministic sensitivity analyses were conducted to estimate 
the confidence around the results. Results: Over the time horizon, compared 
to SoC, TAVR produced an additional 1.61 Life years at an additional cost to the 
health care sector of $777,414 MXP. The ICER was thus $483,022 MXP (35,779 USD) 
per LYG. The sensitivity analysis identified time horizon, discount rate on health 
benefits, probability of leaving intensive care and time of stay in intensive care, 
as the variables with the most impact. The model was insensitive to changes in 
the TAVR acquisition cost, device related complication rates and the probability/ 
cost of additional pacing. ConClusions: In comparison with SoC, TAVR produces 
an increase in life expectancy in patients with SAS that are ineligible for cardiac 
surgery, at an ICER below an internationally accepted cost-effectiveness threshold 
value. These results, and the improvements in health and quality of life observed 
in the clinical studies, identify TAVR as both a clinically effective and cost-effective 
therapy for Mexican patients.
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objeCtives: Atrial Fibrillation (AF) affects 1–2% of the population, and this figure 
is likely to increase in the next 50 years. AF is associated with increased rates of 
death, stroke and other thromboembolic events, heart failure and hospitaliza-
tions, degraded quality of life and reduced exercise capacity. It is suggested that 
patients with AF should be stratified for the risk of stroke and bleedings and that 
most should receive antithrombotic therapy. The aim of this study was to assess 
the cost-effectiveness (CE) of Apixaban against other anticoagulation therapies for 
prevention on non-valvular atrial fibrillation (NVAF), from the private health care 
perspective. Methods: A simulated cohort of 1000 patients with NVAF entered 
a decision-tree model to compare costs and effectiveness of Warfarin (5 mg/24 
hours), Apixaban (5 mg/12 hours), Dabigatran (110 mg/12 hours and 150 mg/12 
hours), and Rivaroxaban (20 mg/24 hours). Effectiveness measures were: stroke, 
bleeding, myocardial infarction (MI) rates and deaths. Local costs were gathered 
from Guatemala’s official databases (US$, 2013) and only direct medical costs were 
considered. The model used a lifetime horizon with a 5% discount. Results: 
Apixaban was the only treatment that consistently prevented all four consid-
ered diseases: 3 MIs, 4 strokes, 85 bleedings and 1 SE avoided when compared to 
Warfarin. Overall costs were US$33708.34 for warfarin, US$24538.68 for Apixaban, 
US$24757.57 for Dabigatran 110 mg, US$24198.23 for Dabigatran 150 mg, and 
US$24252.46 for Rivaroxaban. In terms of QALY’s, Apixaban earned the highest 
amount with 5.740, followed by Rivaroxaban, Dabigatran 150 mg, Dabigatran 110 
mg and Warfarin. In the CE incremental analysis, Apixaban was a cost-effective 
option. Apixaban obtained the highest probability of being cost-effective (45%) 
with a 3 GPB per capita in Guatemala. ConClusions: Apixaban is a Cost-Effective 
option for the Guatemala’s Private Health System.
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objeCtives: To evaluate the cost-effectiveness of rivaroxaban in addition to the 
standard of care (SoC) therapy in the prevention of the risk of CV events and 
bleeding in patients with a recent ACS compared to the placebo in addition to the 
SoC. Methods: A Markov model demonstrating the progression of ACS patients 
from healthy state towards atherosclerotic and bleeding events and to death was 
adapted to the Turkish setting. The cycle length was set as six-months. The analy-
sis was undertaken from a payer perspective. Event rates and treatment effects 
were derived from the ATLAS-2-TIMI clinical trial. 61Utility values for events were 
based on international literature. Costs of each health state included year 2013 
local costs of medications, monitoring and events (TL/ USD currency rate was set 
at 1.70; mid 2013). Incremental cost effectiveness ratios (ICER) per life year (LY) and 
quality-adjusted LY (QALY) gained were calculated. One-way sensitivity analyses 
were conducted to test the robustness of the model. The time horizon was life time 
period. Discount rate was set at 3.5% for economic and clinical inputs. Willingness-
to-pay (WTP) threshold was set as twice the local gross domestic product per 
capita (20,888USD). Results: The total cost of rivaroxaban-treated patients was 
578USD higher compared to SoC. Additional drug costs (676USD) caused by rivar-
oxaban was somewhat offset by reduced costs of and events and interventions 
(98USD). Moreover, rivaroxaban was associated with increments of 0.102LYs and 
0.088QALY leading to an ICER of 5,691USD/LY gained and 6,590USD/QALY gained. 
Sensitivity analyses showed that the cost-effectiveness results are fairly insensi-
tive to most inputs. ConClusions: Rivaroxaban, given its cost-saving effects on 
consequent CV events, improvement in LYs and QALYs, and ICER values below 
WTP threshold, is suggested to be a cost-effective alternative for the prevention 
of CV events in ACS.
A116  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  
PCV79
imPaCt of gEnEriC CloPidogrEl in thE aCutE Coronary syndromE 
managEmEnt of hong kong
Lee V.W.Y., Tsai R.P.C., Chow I.H.I., Yan B.P., Lam Y.Y.
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objeCtives: This study was conducted to compare health and cost outcomes utiliz-
ing either Ticagrelor versus Plavix in the management of acute coronary syndrome 
(ACS) patients, and impact of generic Clopidogrel used in Hong Kong. Methods: A 
decision analytic model was used to perform a cost-effectiveness analysis of treat-
ing ACS patients for one year with Ticagrelor plus aspirin strategy compared with 
Plavix (or generic Clopidogrel) plus aspirin strategy from Hong Kong health care pro-
vider perspective. To estimate discounted (3%) lifetime costs, quality-adjusted life 
years (QALYs), and incremental cost-effectiveness ratios (ICERs). The health states 
in the model included patient in ACS without event, myocardial infarction (MI), and 
death from vascular cause. The model simulates a cohort of 45-year-old patients 
with ACS, and Markov cycle is one year. The time horizon was lifetime (85 years old). 
Event rates were adopted from the PLATO study, and the ACS registry in the Prince of 
Wales Hospital (PWH) in Hong Kong. Probabilistic sensitivity analyses using Monte 
Carlo simulations were conducted to assess parameter uncertainty. Results: 
Compared with the Plavix (or generic Clopidogrel) treatment strategy, the Ticagrelor 
treatment strategy for ACS, STEMI, and UA / NSTEMI patients were associated with 
ICERs of HK$ 34,441(35,304), HK$ 32,753(33,567), HK$ 39,343(40,417) (1US$ = 7.8HK$) 
per QALY gained, respectively. Ticagrelor treatment strategy was cost-effective over 
99% of the Monte Carlo simulation using a cost-effectiveness threshold of < 1x GDP 
per capita of Hong Kong. ConClusions: The Ticagrelor strategy is considered cost-
effective at three times per capita GDP threshold compared with Plavix or generic 
Clopidogrel strategy in the management of ACS patients in Hong Kong. The impact 
of ICER values of generic clopidogrel compared with Plavix is not significant even 
the sextuple cost in Hong Kong.
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objeCtives: Catheter ablation, an expensive procedure with high Atrial Fibrillation 
(AF) recurrence rate, is indicated in patients refractory to drug therapy or in patients 
with drug tolerability issues. The study examines the CE of MRI-guided ablation 
vs. current standard of care (SoC) of ablating all eligible patients in preventing 
AF. Methods: A decision tree model was developed with a payer perspective 
over a 1-year time horizon. Participants of the DECAAF trial (n= 260), prospective 
multicenter-blinded study, were categorized to Utah Stage I (19%), II (41%), III (31%), 
and Stage IV (9%) based on degree of atrial structural remodeling quantified using 
delayed enhancement MRI. Proportion of patients with post ablation AF recurrence 
for Utah Stage I-IV was 16.33%, 30.84%, 45.68%, and 58.33% respectively. Survival 
from outcomes was considered as effectiveness. Selective ablation was defined as 
ablating Stage I and II AF patients and medically managing Stage III and IV patients. 
Recurrence rates from the DECAAF trial and other costs and probabilities from the 
literature were used in the model. Probabilistic sensitivity analysis was conducted 
on all variables in the model. Results: The mean total per patient annual cost in 
the MRI-guided selective ablation cohort was $23,238 compared to $28,659 for the 
SoC ablates all cohorts. However, no significant – clinical or statistical, difference 
in effectiveness was observed. The higher cost of the ablate all cohort was associ-
ated with higher AF recurrence and costs of AF treatment. Probabilistic sensitivity 
analysis demonstrated the similar substantial difference between two procedures. 
The probability associated with AF recurrence in SoC was most sensitive varia-
ble. ConClusions: MRI-guided selective ablation is economically beneficial with 
annual savings of $5,421 per person with same effectiveness compared to current 
SoC. Future research taking QoL and age into account is warranted to help payers 
assess the CE of ablation procedure in AF patients.
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objeCtives: Value-based insurance design (VBID) programs aim to encourage 
patient use of high value health care services, often with the goal of reducing 
overall cost. We investigate a hypothetical VBID program of copay elimination 
for statins to determine if it is cost saving and cost effective. Methods: The 
Archimedes Model was used to simulate the outcomes of increased statin adher-
ence due to copay elimination. 10,000 individuals representative of US population 
who had been prescribed statins were modeled over a 10 year timeframe, sub-
jected to a two-arm virtual trial: one arm represents current care and the other 
arm represents copay elimination. Based on a literature review, statin adherence 
rates were increased by 3% in the copay elimination arm. Statin prices, based 
on generic prices, were $12/mo for Atorastatin80, $4/mo for Simvastatin80, and 
$3/mo for all other Simvastatin doses. Results: The VBID program failed to be 
cost saving, costing insurers $20 per person per year over the 10 year timeframe. 
The program saved 37 life years and 33 QALYs at a discounted cost of $66,000 per 
discounted QALY with 0.03 discount rate. For shorter timeframes the average 
cost remained constant and the program was even less cost effective. Follow-up 
simulations and analyses show that the program is increasingly cost effective in 
high risk subpopulations. For a population(n= 928) ages 60 to 70 with diabetes and 
prior MIs the program became cost saving after 12 years, having saved $94,000 
over 20 years. ConClusions: The proposed VBID program failed to be cost sav-
ing because the benefit of increased statin adherence was small compared to the 
cost of copay elimination for all statin users. This failure to find cost savings is 
consistent with the published observational studies. To achieve cost savings VBID 
programs should be targeted according to individual risk.
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objeCtives: American College of Chest Physicians (ACCP) guideline recommends 
the use oral medication either rivaroxaban or dabigtran in patients who are under-
going major orthopedic surgery and decline injections. This study assessed the 
cost-effectiveness of rivaroxaban verus dabigatran for prevention of venous throm-
boembolism (VTE) and bleeding episode after total hip replacement (THR) surgery 
from Medicare perspective. Methods: A 6-month decision-tree model was devel-
oped to compare the cost-effectiveness of rivaroxaban and dabigatran for THR. 
Treatment efficacy and safety data such as probabilities of distal and proximal deep 
vein thrombosis (DVT), symptomatic pulmonary embolism (PE), and major bleeding 
were derived from randomized controlled trials and systematic reviews. Cost of 
medications were derived from the Redbook (2012) and cost of DVT, PE and major/
minor bleeding episodes were based on diagnosis code related payment (2009). 
Guidelines consistent diagnosis procedure for VTE and current procedure terminol-
ogy (CPT) codes were utilized for determining procedure costs. All cost data was 
adjusted to 2012 dollars. A discount rate of 3% was applied to base-case analysis 
and sensitivity analysis were conducted to characterize uncertainty in the decision 
model. Results: The prophylaxis medication cost for rivoraxaban and dabigatran 
was $422.51 and $392.61, respectively for per person per event. The cost of treating 
major bleeding episode and VTE were $14,548.09 and $14,114.80, respectively per 
person per event. There were absence of any head-to-head studies comparing the 
dabigatran and rivaroxaban. Compared to standards heparin regimen, rates of bleed-
ing events did not differ significantly between dabigatran etexilate and rivaroxaban. 
However, the rates of having VTE event were higher in rivaroxaban compared to The 
prophylaxis treatment with dabigatran was $164.40 less costly than rivaroxaban for 
prevention of VTE and bleeding episode in patient undergoing THR. ConClusions: 
Dabigatran and rivaroxaban share similar adverse events profiles, however, dabi-
gatran was found to be more cost-saving compared to rivaroxaban.
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thE Cost-EffECtiVEnEss of dEtECting arrhythmia With imPlantablE 
looP rECordErs in thE unitEd statE of amEriCa
Rogers J1, Chang S.2, Quiroz M.E.3, Madden T.3, Diamantopoulos A.4, Mollenkopf S.A.5
1Scripps Clinic Torrey Pines, La Jolla, CA, USA, 2Symmetron Limited, Elstree Herts, UK, 3Medtronic, 
Mounds View, MN, USA, 4Symmetron Limited, Elstree, UK, 5Medtronic, Inc., Mounds View, MN, 
USA
objeCtives: To evaluate the cost-effectiveness of diagnosis with an ILR following 
Standard Testing (ST) after a syncopal event from a United States payer perspec-
tive. Methods: This analysis considers all costs of diagnosis via ST and ILR, the 
costs and consequences of recurrent syncope, and the cost of arrhythmia treat-
ment following diagnosis. A Markov model was developed to reflect the recurrence 
of syncopal events in undiagnosed patients. Due to documented differences in 
the prevalence of arrhythmia between patients with suspected arrhythmia and 
patients with unexplained syncope we considered the two populations separately, 
each over a 10-year time horizon. All costs and consequences were discounted at 
a 3% annual rate. Results: The results are similar for suspected arrhythmia and 
unexplained syncope. In the suspected arrhythmia population, the incremental cost 
of the ILR strategy is $14,712. The incremental Quality Adjusted Life Years (QALY) are 
estimated to be between 0.2806 and 0.4282, and the incremental cost-effectiveness 
ratio (ICER) is between $34,400 and $52,400. The syncopal events avoided with ILR 
are 402 per 1,000 patients. In the unexplained syncope population the incremental 
costs and effects are lower compared to the previous case: $13,800, and between 
0.2174 and 0.3317 QALYs gained. The ICER is between $41,600 and $63,500 per QALY 
gained. The number of syncopal events avoided with ILR is 311 per 1,000 patients. 
In 1,000 patients the ILR strategy is estimated to identify between 300 and 380 more 
arrhythmia cases compared to ST in the two populations. ConClusions: When 
considering all costs in combination with the syncopal events avoided and quality 
of life (QoL), ILR arrhythmia diagnosis is a cost-effective alternative to ST. The use 
of ILR increases the diagnostic yield in both populations and guides treatment in 
more patients compared to ST.
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objeCtives: The main goal of treatments for AF is stroke prevention since the 
annual risk of stroke is 5–6 times greater in patients with AF than in people with 
a normal heart rhythm. [1] The incidence of AF increases from less than 0.1% per 
year in those under 40 years old to exceed 1.5% per year in women and 2% in 
men older than 80. [2] This study assesses the cost-effectiveness (CE) of Apixaban 
versus other anticoagulation therapies for prevention on NVAF, from the private 
health care perspective. Methods: A Markov decision-tree model was made to 
compare costs and effectiveness of Warfarin (5 mg/24 hours), Apixaban (5 mg/12 
hours), Dabigatran (110 mg/12 hours and 150 mg/12 hours), and Rivaroxaban (20 
mg/24 hours) in a simulated cohort of 1000 patients with AF. Effectiveness meas-
ures were: stroke, bleeding, myocardial infarction (MI) rates and deaths. Local costs 
were gathered from Trinidad’s Private Health System databases (US$, 2013) and only 
